P/E ratio for Aurobindo Pharma (AUROPHARMA.NS)
P/E ratio as of April 2024 (TTM): 32.2
According to Aurobindo Pharma 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 32.2412. At the end of 2022 the company had a P/E ratio of 12.9.
P/E ratio history for Aurobindo Pharma from 2012 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | 12.9 | -14.29% |
| 2021 | 15.0 | 50.1% |
| 2020 | 10.00 | -4.16% |
| 2019 | 10.4 | -43.95% |
| 2018 | 18.6 | 12.74% |
| 2017 | 16.5 | -1.93% |
| 2016 | 16.8 | -38.33% |
| 2015 | 27.3 | 38.06% |
| 2014 | 19.8 | 34.75% |
| 2013 | 14.7 | -22.03% |
| 2012 | 18.8 |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.